Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
PANACEA BIOTECH ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PANACEA BIOTECH Mar-23 |
ADCOCK INGRAM Jun-14 |
PANACEA BIOTECH/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 191 | 319 | - | |
Low | Rs | 107 | 230 | - | |
Sales per share (Unadj.) | Rs | 75.1 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | -5.5 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 0.9 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 137.7 | 74.5 | - | |
Shares outstanding (eoy) | m | 61.25 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.0 | 2.9 | 68.7% | |
Avg P/E ratio | x | -27.1 | -11.5 | 235.9% | |
P/CF ratio (eoy) | x | 170.0 | -13.9 | -1,226.8% | |
Price / Book Value ratio | x | 1.1 | 3.7 | 29.4% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 9,142 | 46,340 | 19.7% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 1,265 | 2,908 | 43.5% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,599 | 16,016 | 28.7% | |
Other income | Rs m | 517 | 112 | 460.6% | |
Total revenues | Rs m | 5,116 | 16,128 | 31.7% | |
Gross profit | Rs m | 47 | -2,775 | -1.7% | |
Depreciation | Rs m | 391 | 691 | 56.6% | |
Interest | Rs m | 44 | 434 | 10.2% | |
Profit before tax | Rs m | 128 | -3,788 | -3.4% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 466 | 237 | 196.6% | |
Profit after tax | Rs m | -337 | -4,036 | 8.4% | |
Gross profit margin | % | 1.0 | -17.3 | -5.9% | |
Effective tax rate | % | 363.5 | -6.2 | -5,817.8% | |
Net profit margin | % | -7.3 | -25.2 | 29.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 5,623 | 11,730 | 47.9% | |
Current liabilities | Rs m | 3,297 | 6,600 | 50.0% | |
Net working cap to sales | % | 50.6 | 32.0 | 157.9% | |
Current ratio | x | 1.7 | 1.8 | 96.0% | |
Inventory Days | Days | 59 | 111 | 52.9% | |
Debtors Days | Days | 48 | 124 | 38.5% | |
Net fixed assets | Rs m | 7,028 | 6,838 | 102.8% | |
Share capital | Rs m | 61 | 74 | 82.4% | |
Net worth | Rs m | 8,436 | 12,571 | 67.1% | |
Long term debt | Rs m | 202 | 4,418 | 4.6% | |
Total assets | Rs m | 12,712 | 23,747 | 53.5% | |
Interest coverage | x | 3.9 | -7.7 | -50.3% | |
Debt to equity ratio | x | 0 | 0.4 | 6.8% | |
Sales to assets ratio | x | 0.4 | 0.7 | 53.6% | |
Return on assets | % | -2.3 | -15.2 | 15.2% | |
Return on equity | % | -4.0 | -32.1 | 12.5% | |
Return on capital | % | 2.0 | -19.8 | -10.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -4,225 | 1,367 | -309.0% | |
From Investments | Rs m | 4,303 | -420 | -1,025.2% | |
From Financial Activity | Rs m | -184 | 4,009 | -4.6% | |
Net Cashflow | Rs m | -105 | 4,957 | -2.1% |
Compare PANACEA BIOTECH With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare PANACEA BIOTECH With: SOURCE NATURAL FOODS DECIPHER LABS ALEMBIC FDC LINCOLN PHAR
It was indeed a volatile trading session for Indian share markets yesterday.